Displaying drugs 10876 - 10900 of 11604 in total
Melperone
Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union . It has been well established in the treatment of confusion, anxiety, restlessness (particularly in...
Investigational
Matched Description: … Melperone has been used for a span of greater than 30 years in the European Union [L1316]. ... Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316]. …
Didesmethylrocaglamide
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of …
V590
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational
Matched Description: … By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one ... Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow …
Norclozapine
ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Investigational
Matched Description: … or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a …
XL820
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
Matched Description: … XL820 is a solid. ... receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a …
Sparteine
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate …
Cirazoline
Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.
Cirazoline has also been shown to decrease food...
Experimental
Matched Description: … Cirazoline acts on a number of α adrenergic receptors. ... It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. …
SCB-2019
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture.
The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a...
Investigational
Matched Description: … SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID ... As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908 …
V-SARS
COVID-19 convalescent plasma is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus. This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form. Immunitor Inc., the sponsor, is currently testing this oral...
Investigational
Matched Description: … the sponsor, is currently testing this oral vaccine for immunogenicity in 20 healthy volunteers in a ... concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a …
CG7870
CG7870 is an oncolytic virus therapy for prostate cancer. It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Investigational
Matched Description: … It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment …
NAV 1800
RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.
Investigational
Matched Description: … RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG …
Ponazuril
Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Vet approved
Matched Description: … Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for …
(5E,7E,9)-decatrien-2-one
An compound produced by Fomitopsis betulina, an edible fungus commonly called the birch polypore. Similar to (5Z,7E,9)-decatrien-2-one, it has a strong pineapple aroma.
Experimental
Matched Description: … Similar to [(5Z,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116] …
(5Z,7E,9)-decatrien-2-one
An compound produced by Fomitopsis betulina, an edible fungus commonly called the birch polypore. Similar to (5E,7E,9)-decatrien-2-one, it has a strong pineapple aroma.
Experimental
Matched Description: … Similar to [(5E,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116] …
2'-Fucosyllactose
2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Investigational
Matched Description: … Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a …
HTPEP-001
HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational
Matched Description: … HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta …
Survodutide
Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)).
Investigational
Matched Description: … Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide …
Mazdutide
Mazdutide is under investigation in clinical trial NCT06143956 (A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-specific-appendices (Isas) in Adult Participants With Obesity or Overweight).
Investigational
Matched Description: … Mazdutide is under investigation in clinical trial NCT06143956 (A Chronic Weight Management Master Protocol …
Dazostinag
Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent …
Pyroquilon
Pyroquilon is a commercial blasticide which binds in the naphthol pocket of fungal trihydroxynaphthalene reductase active site.
Experimental
Matched Description: … Pyroquilon is a commercial blasticide which binds in the naphthol pocket of fungal trihydroxynaphthalene …
Narnatumab
Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).
Investigational
Matched Description: … Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid …
TW-37
TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.
Investigational
Matched Description: … TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.[A253157] …
CGX-1321
CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling.
Investigational
Matched Description: … CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling. …
MEDI-491
MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.
Investigational
Matched Description: … MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins. …
BHT-3034
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
Matched Description: … BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis …
Displaying drugs 10876 - 10900 of 11604 in total